PHARMING GROUP N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.874 EUR | -0.91% |
|
-2.73% | -15.23% |
| 05-08 | Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024 | |
| 05-08 | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
ETFs positioned on Pharming Group N.V.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 2 M€ | -.--% | ||
| 0.05% | 7 M€ | -.--% | - | |
| 0.02% | 0 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | -2.25% | - | |
| 0.00% | 0 M€ | -2.58% | - | |
| 0.00% | 0 M€ | -3.22% | - |
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.882
EUR
Average target price
1.933
EUR
Spread / Average Target
+119.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.23% | 640M | |
| +30.38% | 684B | |
| +29.14% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.89% | 240B | |
| +9.04% | 208B | |
| -7.77% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- PHARM Stock
- Funds and ETFs Pharming Group N.V.
